Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258427 · ClinicalTrials.gov registry record · Phase 2
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
A Phase 2 study of Fanconi Anemia, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00258427 is a Phase 2 study of Fanconi Anemia that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 14 participants, below the 335-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00258427, a Phase 2 study of Fanconi Anemia, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: A bone marrow or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving combination chemotherapy before a donor stem cell transplant may make the transplant more likely to work. This may be an effective treatment for patients with high risk Fanconi's anemia. PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating high risk patients who are undergoing a donor stem cell transplant for Fanconi's anemia.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- BIOLOGICAL filgrastim
- DRUG busulfan
- BIOLOGICAL anti-thymocyte globulin
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2002-03-26 |
| Est. Completion | 2020-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00258427
The ClinicalTrials.gov registry entry for NCT00258427 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 335-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (96% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fanconi Anemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00258427 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00258427 about?
NCT00258427 is a clinical study titled "Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia". RATIONALE: A bone marrow or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving combination chemotherapy before a donor stem cell transplant may make the transplant more likely to work. This may be an effective treatment for patients...
What is the current status of trial NCT00258427?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2002-03-26. Estimated completion is 2020-10-10.
What conditions does trial NCT00258427 study?
This clinical trial studies the following conditions: Fanconi Anemia.
What interventions are being tested in trial NCT00258427?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), filgrastim (BIOLOGICAL), busulfan (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00258427?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00258427 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fanconi Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
RECRUITING · Phase 2
-
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
RECRUITING · Phase 2
-
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
RECRUITING · Phase 2
-
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
ACTIVE NOT RECRUITING · Phase 2
-
Eltrombopag for People With Fanconi Anemia
ACTIVE NOT RECRUITING · Phase 2
-
Hematopoietic Stem Cell Transplant for Fanconi Anemia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.